SAN DIEGO, February 24, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the...
— Oral administration of PRTX007 exhibits favorable safety profile, rapid conversion to TLR7 agonist PRX034, and activation of the innate immune system, without an increase in proinflammatory factors — SAN DIEGO, February 14, 2022 – Primmune Therapeutics, a biotech...
SAN DIEGO, February 7, 2022 – Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat viral diseases and cancers, today announced that they will present data related to PRTX007, a novel, orally administered, small molecule...
SAN DIEGO, November 4, 2021 – Primmune Therapeutics today announced that it has received $8.4 million in a second tranche of the Company’s Series A financing. The total proceeds for the equity raised in the Series A was $31.4 million. These funds will be used to...
SAN DIEGO, November 2, 2021 – Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including...
SAN DIEGO, February 5, 2021 – Today, Primmune Therapeutics announced the appointment of Rich Daniels as Chief Operating Officer, Scott Zook as Senior Vice President, Global Manufacturing and Randy Adams as Senior Advisor, Commercial Development. “The appointments of...
SAN DIEGO, January 12, 2021 – Today, Primmune Therapeutics announced the close of its Series A financing round with the addition of $4.0 million from Bioqube Ventures, a European life sciences venture capital firm. This brings the total of the Series A financing raise...
Primmune received a Paycheck Protection Program (“PPP”) loan from Silicon Valley Bank on April 30, 2020. On November 4, 2020, Primmune paid its PPP loan in full.
Financing co-led by seasoned healthcare investors, CAM Capital and Polaris Partners SAN DIEGO, October 27, 2020 — Primmune Therapeutics today announced the initial closing of a $27.4 million Series A financing to advance the development of novel...
SAN DIEGO, March 31, 2020 – Primmune Therapeutics announced today that it has selected PRTX007 as its lead clinical development candidate for SARS-CoV-2 (the virus that causes COVID-19) and for oncology indications. “PRTX007 is an oral small molecule that specifically...
